Comment: here you go a checklist.

(See in situ)


here you go a checklist.

LET'S LEARN ABOUT CBD!

Let's look at some facts about the uses of Cannabidiol(CBD), and how it could affect Big Pharma.

Remember, Cannabidiol is a non-psychoactive cannabinoid and is the active ingredient in Dixie X medicinal hemp products from Dixie Elixirs & Edibles.

* Cannabidiol is an anti-spasmodic. (suppresses muscle spasms)

That means it could replace:

-hyoscyamine (Levsin SL or HyoMax SL or Levbid)
-atropine/hyoscyamine/phenobarbital/scopolamine (Donnatal)
-methscopolamine (Pamine)
-scopolamine (Scopace)
-chlordiazepoxide/clidinium (Librax)
-dicyclomine (Bentyl)

Common side effects of current anti-spasmodic drugs include Flatulence and bloating, Heartburn, Constipation, and Dry mouth.

Cannabidiol does not do those things.

* Cannabidiol is an antiepileptic. (treats seizures)

That means it could replace:
- phenytoin (Dilantin)
- valproic acid (Depakote)
- phenobarbital
- lamotrigine (Lamictal)
- carbamazepine (Tegretol)
- topiramate (Topamax)
- oxcarbazepine (Trileptal)
- zonisamide (Zonegran)
- gabapentin (Neurontin)
- levetiracetam (Keppra)
- pregabalin (Lyrica)
- clonazepam (Klonopin)
- lacosamide (Vimpat)
- rufinamide (Banzel)
- vigabatrin (Sabril)

A brief compilation of the side effects of most antiepileptic drugs are listed below. These are the most common and most worrisome, not a full list. Every seizure medicine can sometimes cause side effects of fatigue, dizziness, unsteadiness, blurry vision, stomach upset, headaches, and reduced resistance to colds, memory and thinking problems. Weight gain tends to occur with valproic acid (Depakote), gabapentin (Neurontin), pregabalin (Lyrica) and carbamazepine (Tegretol, Carbatrol). Weight loss tends to occur with topiramate (Topamax), zonisamide (Zonegran) and felbamate (Felbatol).

Cannabidiol does not do those things.

* Cannabidiol is an anti-inflammatory. (reduces inflammation)

That means it could replace:
-asprin
-ibuprofen
-diclofenac (Cambia, Cataflam, Voltaren)
-etodolac (Lodine)
-fenoprofen (Nalfon)
-flurbiprofen (Ansaid)
-naproxen (Anaprox, Naprosyn)
-oxaprozin (Daypro)

The widespread use of NSAIDs has meant that the adverse effects of these drugs have become increasingly prevalent. The two main adverse drug reactions (ADRs) associated with NSAIDs relate to the gastrointestinal (GI) and renal effects of NSAIDs.

These effects are dose-dependent, and in many cases severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death, limiting the use of NSAID therapy. An estimated 10-20% of NSAID patients experience dyspepsia, and NSAID-associated upper gastrointestinal adverse events are estimated to result in 103,000 hospitalizations and 16,500 deaths per year in the United States, and represent 43% of drug-related emergency visits. Many of these events are avoidable; a review of physician visits and prescriptions estimated that unnecessary prescriptions for NSAIDs were written in 42% of visits.

NSAIDs, like all drugs, may interact with other medications. For example, concurrent use of NSAIDs and quinolones may increase the risk of quinolones' adverse central nervous system effects, including seizure

Cannabidiol does not do those things.

* Cannabidiol is an anxiolytic. (reduces anxiety)

That means it could replace:
-Alprazolam (Xanax)
-Chlordiazepoxide (Librium)
-Clonazepam (Klonopin, Rivotril)
-Diazepam (Valium)
-Etizolam (Etilaam)
-Lorazepam (Ativan)
-Oxazepam (Serax)

The most common side-effects are related to their sedating and muscle-relaxing action. They include drowsiness, dizziness, and decreased alertness and concentration. Lack of coordination may result in falls and injuries, in particular, in the elderly. Another result is impairment of driving skills and increased likelihood of road traffic accidents. Decreased libido and erection problems are a common side effect. Depression and disinhibition may emerge. Hypotension and suppressed breathing may be encountered with intravenous use. Less common side effects include nausea and changes in appetite, blurred vision, confusion, euphoria, depersonalization and nightmares. Cases of liver toxicity have been described but are very rare.

Cannabidiol does not do those things.

* Cannabidiol is an anti-emetic. (reduces nausea)

That means it could replace:
-Dolasetron (Anzemet)
-Granisetron (Kytril, Sancuso)
-Ondansetron (Zofran)
-Tropisetron (Navoban)
-Palonosetron (Aloxi)
-Mirtazapine (Remeron)
-Domperidone
-Olanzapine
-Droperidol
-Alizapride
-Prochlorperazine
-Metoclopramide (Reglan)
-Cyclizine
-Diphenhydramine (Benadryl)
-Dimenhydrinate (Gravol, Dramamine)
-Doxylamine
-Meclozine (Bonine, Antivert)
-Hydroxyzine
-Lorazepam

These don't have all that much in the way of side effects.

So, Cannabidiol is looking pretty effective in a number of things, isn't it? All of what I posted above doesn't even talk about how:

* Cannabidiol has been shown to inhibit cancer cell growth.
* Cannabidiol is an immunomodulator and helps the immune system function more efficiently.
* Cannabidiol is a neuroprotectant and a powerful antioxidant.
* Cannabidiol is an anti-psychotic

CBD Informational Works Cited

Galal AM, Slade D, Gul W, El-Alfy, AT, Ferreira D, Elsohly, MA. Naturally Occuring and Related Synthetic Cannabinoids and their potential Therapeutic Applications. Recent Patents on CNS Drug Discovery. 2009; 4:112-136.

Gieringer, Dale, Rosenthal, Ed, Carter, Gregory T. Marijuana Medical Handbook. Oakland: Quick American, 2008.

Iversen, Leslie L. The Science of Marijuana. New York: Oxford University Press, 2008.

Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: Pharmacol. 2002; 42 (11 Suppl):11S-19S

Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963; 19(12): 2073-8.

Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses. 2006;66(2): 234-46.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008 Sept; 30(3):271-80.